ライフサイエンスコーパス: skeletal-related event

1 ed with a 31% decreased risk of developing a skeletal-related event.

2 a skeletal-related event, and time to first skeletal-related event.

3 te cancer, primarily to improve survival and skeletal related events.

4 te bone turnover and result in bone loss and skeletal-related events.

5 icant morbidity and mortality as a result of skeletal-related events.

6 delayed pain progression, and prevention of skeletal-related events.

7 irst skeletal-related event and incidence of skeletal-related events.

8 patients are at greatest risk of developing skeletal-related events.

9 Skeletal metastases may result in skeletal-related events.

10 ted that zoledronic acid reduces the risk of skeletal-related events.

11 eveloping bone metastases and, subsequently, skeletal-related events.

12 spinal cord compression are also considered skeletal-related events.

13 nhematologic adverse events (AEs), including skeletal-related events.

14 o, 0.40; P<0.001), and the time to the first skeletal-related event (16.7 vs. 13.3 months; hazard rat

15 roportional hazards models for time to first skeletal-related event and incidence of skeletal-related

16 minobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone m

17 and pain, the proportion of patients with a skeletal-related event, and time to first skeletal-relat

18 ree survival, time to castration resistance, skeletal-related events, and adverse effects.

19 eported here are on pain, HRQOL, symptomatic skeletal-related events, and time to first opiate use fo

20 A prior skeletal-related event, baseline performance status, and

21 ent arm, which was particularly true for the skeletal-related events bone pain (5 years, 8.3% vs 2 ye

22 multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyel

23 ckbuster therapies that significantly reduce skeletal-related events, but the disease remains incurab

24 ients in the placebo group had experienced a skeletal-related event by data cutoff.

25 d the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed

26 preferable to ibandronic acid in preventing skeletal-related events caused by bone metastases.

27 the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, sp

28 Secondary endpoints were time to first skeletal-related event (defined as radiation therapy or

29 The proportions of skeletal-related events did not differ significantly bet

30 azard ratio, 0.35), the time until the first skeletal-related event (hazard ratio, 0.72), a complete

31 ared to zoledronic acid in the prevention of skeletal related events in men with bone metastases.

32 ated outcomes and delays occurrence of first skeletal-related event in chemotherapy-naive men with me

33 Median time to first skeletal-related event in the enzalutamide (n=800) and p

34 was also associated with a lower risk of any skeletal-related event in the subsets of patients with (

35 rtant because they decrease the incidence of skeletal-related events in many tumour types and can com

36 Osteoclast-targeted agents reduce skeletal-related events in mCRPC.

37 ve shown efficacy in preventing and delaying skeletal-related events in patients with a variety of so

38 he standard of care for reducing the risk of skeletal-related events in patients with bone lesions fr

39 Bisphosphonates prevent skeletal-related events in patients with metastatic brea

40 have been shown to decrease the incidence of skeletal-related events in patients with metastatic cast

41 idronate (PAM) is recommended for preventing skeletal-related events in patients with MM.

42 Median time to first skeletal-related events in the enzalutamide group was 31

43 tastatic breast cancer, resulting in painful skeletal-related events including bone loss and fracture

44 nosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease st

45 Skeletal-related events may result both from disease and

46 secondary endpoints, including occurrence of skeletal-related events, measures of pain control, and p

47 h-related quality of life (HRQoL), pain, and skeletal-related events observed during this trial.

48 ity endpoint was the frequency and timing of skeletal-related events over 96 weeks, analysed using a

49 ion, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 5

50 We assessed data for pain control and skeletal-related events prospectively collected as part

51 ival improved independently of prevention of skeletal-related events, showing that zoledronic acid ha

52 Overall survival (OS) and skeletal-related event (SRE) data have been reported for

53 was proportion of patients with at least one skeletal-related event (SRE), defined as pathologic frac

54 endpoints were progression-free survival and skeletal-related event (SRE).

55 gesic use, the proportion of patients with a skeletal-related event (SRE; defined as pathologic fract

56 edronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced

57 , patients experiencing one or more on-study skeletal-related events (SRE), and safety were also eval

58 o asymptomatic bone metastases in preventing skeletal-related events (SRE).

59 Total skeletal related events (SREs), including surgery for pa

60 ended by international guidelines to prevent skeletal-related events (SREs) among patients with metas

61 Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-re

62 and risedronate) and treatment/prevention of skeletal-related events (SREs) in multiple myeloma and b

63 th zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast c

64 l and economic burden of bone metastasis and skeletal-related events (SREs) in prostate cancer, and d

65 Purpose Skeletal-related events (SREs) such as pathologic fractu

66 ZOL significantly reduced skeletal-related events (SREs), and improved progression

67 Denosumab and radium-223 reduce the risk of skeletal-related events (SREs), but only radium-223 impr

68 s with bone metastases to reduce the risk of skeletal-related events (SREs).

69 leading to severe pain, fractures, and other skeletal-related events (SREs).

70 atient: prolongation of life or reduction in skeletal-related events (SREs).

71 sion-free survival (CPFS) (pain progression, skeletal-related events [SREs], or death) and cost-effec

72 ledronic acid group had a lower incidence of skeletal-related events than did those in the clodronic

73 oints were overall survival (OS) and time to skeletal-related events (tSREs).

74 Median time to first symptomatic skeletal-related event was not reached for either treatm

75 pulation, median time to occurrence of first skeletal-related event was significantly longer with abi

76 80) with zoledronic acid; the rate ratio for skeletal-related events was 1.148 (95% CI 0.967-1.362).

77 Annual rates of skeletal-related events were 0.499 (95% CI 0.454-0.549)

78 Analyses of skeletal-related events were also done in the intention-

79 Skeletal-related events were noted in 20% of patients.

80 to prostate-specific antigen progression, or skeletal-related events) were observed.

81 mide, are shown to decrease the incidence of skeletal-related events, whereas the radiopharmaceutical

82 We measured time to first occurrence of skeletal-related events, which we defined as pathologica

83 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (

84 one therapy; and whether they had a previous skeletal-related event within the last 3 months or had p